Remarkably, the effects of SPRYD7 upregulation were more striking in poorly or non-metastatic KM12C and SW480 CRC cells, respectively, as these cells improved their tumorigenic and metastatic properties, matching or surpassing those of their corresponding isogenic metastatic KM12SM and SW620 CRC cells, respectively. This evidence concerns the gene SPRYD7 and colorectal carcinoma.